8-K
filed October 8, 2025, 7:59 PM ET
ticker KPTI
CIK 0001503802
debt
confidence high
sentiment negative
materiality 0.95
KPTI closes $67.5M debt package, note exchanges & $8.75M equity; runway into Q2 2026
Karyopharm Therapeutics Inc.
- $27.5M new term loan (SOFR+10.25%), $25M interest/royalty deferrals, $15M liquidity covenant relief.
- Exchanged $15M 2029 notes for new 9% 2028 notes and $24.25M Oct 2025 notes for stock & warrants.
- Raised $8.75M via private placement of 7.2M shares and warrants at $6.64 exercise price.
- Pro forma cash ~$36M; shares outstanding ~15.9M; total debt $112.5M term loan, $15M+$103.5M convert notes.
- Lenders get board observer; interest payments paid-in-kind through March 2026, cash starts June 2026.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued shares of common stock of common stock to holders of convertible notes for $15.0 million aggregate principal amount of the Company’s convertible notes due 2029.
- Security
- common stock
- Shares
- shares of common stock
- Purchaser
- holders of convertible notes
- Consideration
- $15.0 million aggregate principal amount of the Company’s convertible notes due 2029
Exact text from the filing
an exchange of $15.0 million aggregate principal amount of the Company’s convertible notes due 2029 for shares of common stock
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued newly issued warrants to purchase an aggregate of 5,918,358 shares of common stock with an exercise price of $6.64 per share of warrant to accredited investors for $8.75 million.
- Security
- warrant
- Shares
- newly issued warrants to purchase an aggregate of 5,918,358 shares of common stock with an exercise price of $6.64 per share
- Purchaser
- accredited investors
- Consideration
- $8.75 million
Exact text from the filing
common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued 7,223,982 newly issued shares of common stock of common stock to accredited investors for $8.75 million.
- Security
- common stock
- Shares
- 7,223,982 newly issued shares of common stock
- Purchaser
- accredited investors
- Consideration
- $8.75 million
Exact text from the filing
common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued shares of common stock and warrants to purchase shares of common stock of common stock to holders of convertible notes for $24.25 million aggregate principal amount of the Company’s convertible notes due October 15, 2025.
- Security
- common stock
- Shares
- shares of common stock and warrants to purchase shares of common stock
- Purchaser
- holders of convertible notes
- Consideration
- $24.25 million aggregate principal amount of the Company’s convertible notes due October 15, 2025
Exact text from the filing
an exchange of $24.25 million aggregate principal amount of the Company’s convertible notes due October 15, 2025 for shares of common stock and warrants to purchase shares of common stock
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued newly issued pre-funded warrants to purchase an aggregate of 2,913,136 shares of common stock of warrant to accredited investors for $8.75 million.
- Security
- warrant
- Shares
- newly issued pre-funded warrants to purchase an aggregate of 2,913,136 shares of common stock
- Purchaser
- accredited investors
- Consideration
- $8.75 million
Exact text from the filing
common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.